Basic information Safety Related Supplier

ChemicalBook Product Catalog Isomazole

1/1

Isomazole NEW

$146.00 1mg

$350.00 5mg

$530.00 10mg

Min. Order
Purity98.66%
Cas No86315-52-8
Supply Ability10g
Update time2026-04-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Isomazole
CAS No	86315-52-8
EC-No
Min. Order
Purity	98.66%
Supply Ability	10g
Release date	2026/04/13

Product Introduction

Bioactivity

Name	Isomazole
Description	Isomazole is a novel orally available phosphodiesterase (PDE) inhibitor with calcium-sensitizing properties that inhibits PDE3 and PDE4.
In vivo	Isomazole (10 and 20 micrograms/kg/min; ) to 10 awake dogs with right-sided congestive heart failure produced by pulmonary artery constriction and tricuspid valve avulsion found that increased cardiac output, heart rate, right ventricular and left ventricular (LV) dP/dt, LVdP/dt/P and decreased aortic pressure and total peripheral vascular resistance. Simultaneously, blood flow increased to myocardium, quadriceps muscle, brain and splanchnic beds, whereas vascular resistance decreased. Furthermore, Isomazole increased LV oxygen consumption and decreased trans-coronary arteriovenous oxygen difference. Angiotensin II was infused to restore mean aortic pressure to base-line values during Isomazole infusion; however, despite the return of aortic pressure to base-line values, cardiac output, LVdP/dt, and LVdP/dt/P remained elevated. The systemic and regional hemodynamic effects of Isomazole were unaffected by pretreatment with propranolol and mecamylamine. Thus, Isomazole exerted positive inotropic, chronotropic, and vasodilator effects in congestive heart failure dogs. The inotropic effect of Isomazole was independent of the decrease in aortic pressure, and the hemodynamic effects of Isomazole were not mediated via the autonomic nervous system. Furthermore, the decrease in trans-coronary arteriovenous oxygen difference suggests that Isomazole exerted an active coronary vasodilator action which may improve the myocardial oxygen demand/supply ratio.[2]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 60 mg/mL (208.81 mM), Sonication is recommended.
Keywords	PDE4 \| PDE3 \| Isomazole
Inhibitors Related	Balipodect \| Theophylline monohydrate \| D(+)-Raffinose pentahydrate \| Theobromine \| Apremilast \| Isoprenaline hydrochloride \| Indomethacin \| Icariin \| Theophylline \| Vardenafil hydrochloride \| Sildenafil citrate \| Doxofylline
Related Compound Libraries	Bioactive Compound Library \| ReFRAME Related Library \| Multi-Target Compound Library \| Inhibitor Library \| Anti-Cardiovascular Disease Compound Library \| Metabolism Compound Library \| Orally Active Compound Library \| Bioactive Compounds Library Max \| Human Metabolite Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy